WhaleCreep

Avidity Partners Management LP 13F holdings, Q2 2025

Hedge fundSEC filingsCompare with another fundHoldings as of 2025-06-30, filed 2025-08-14

Avidity Partners Management LP disclosed 55 US equity positions worth $498.8m in its Q2 2025 13F filing. Its largest position is CGON at 7.8% of the reported book, followed by BSX and NTRA. Versus Q1 2025 it opened 17 new positions, added to 17, reduced 13 and exited 25.

$499m
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
55
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
7.8%
Largest position
The largest single position as a share of the reported equity book.
49.1%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
28
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q1 2025: 17 new, 17 added, 13 reduced, 25 exited

50 of 55
CGON CG ONCOLOGY INCHealthcare7.8%$39.0m1.50m+53%added
BSX BOSTON SCIENTIFIC CORPHealthcare6.9%$34.6m321,800−4.2%reduced
NTRA NATERA INCHealthcare6.8%$33.7m199,300+67%added
DNTH DIANTHUS THERAPEUTICS INCHealthcare6.5%$32.5m1.74m+1.3%added
EXK EXACT SCIENCES CORPBasic Materials3.8%$18.9m355,000+0.6%added
THC TENET HEALTHCARE CORPHealthcare3.7%$18.7m106,000+47%added
DXCM DEXCOM INCHealthcare3.7%$18.4m210,500+17%added
DHR DANAHER CORP DELHealthcare3.6%$17.7m89,700+102%added
HNGE HINGE HEALTH INCHealthcare3.3%$16.7m322,344–new
ISRG INTUITIVE SURGICAL INCHealthcare3.0%$14.7m27,100–new
GMAB GENMAB A/SHealthcare2.7%$13.4m650,000–new
RGEN REPLIGEN CORPHealthcare2.7%$13.2m106,500–new
TMO THERMO FISHER SCIENTIFIC INCHealthcare2.4%$12.0m29,600+91%added
TEVA TEVA PHARMACEUTICAL INDS LTDHealthcare2.3%$11.6m689,500+43%added
JBIO JADE BIOSCIENCES INCHealthcare2.3%$11.3m1.13m–new
PHAT PHATHOM PHARMACEUTICALS INCHealthcare2.0%$10.2m1.06m+33%added
UNH UNITEDHEALTH GROUP INCHealthcare2.0%$10.0m32,000−37%reduced
MCK MCKESSON CORPHealthcare2.0%$9.9m13,500–new
AXSM AXSOME THERAPEUTICS INC.Healthcare2.0%$9.9m94,500+23%added
COR CENCORA INCHealthcare2.0%$9.8m32,800−17%reduced
HQY HEALTHEQUITY INCHealthcare1.9%$9.6m92,000+18%added
EHC ENCOMPASS HEALTH CORPHealthcare1.8%$9.1m74,000–new
RVMD REVOLUTION MEDICINES INCHealthcare1.7%$8.4m228,600+7.3%added
AKROEUR AKERO THERAPEUTICS INC–1.4%$7.2m134,000+135%added
OMDA OMADA HEALTH INCHealthcare1.4%$7.1m390,600–new
BEAM BEAM THERAPEUTICS INCHealthcare1.4%$7.0m409,400−42%reduced
HUM HUMANA INCHealthcare1.4%$6.7m27,600−66%reduced
CATX PERSPECTIVE THERAPEUTICS INC–1.3%$6.4m1.86m−15%reduced
OGN ORGANON & COHealthcare1.2%$6.2m640,000+20%added
BBIO BRIDGEBIO PHARMA INCHealthcare1.2%$6.0m140,000+87%added
INSM INSMED INCHealthcare1.2%$5.9m59,000−45%reduced
MDGL MADRIGAL PHARMACEUTICALS INCHealthcare1.2%$5.8m19,000–new
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare1.1%$5.6m154,000−52%reduced
CNTX CONTEXT THERAPEUTICS INC–1.0%$4.9m7.48m0.0%held
ORKA ORUKA THERAPEUTICS INCHealthcare0.8%$3.9m352,1240.0%held
IMUX IMMUNIC INCHealthcare0.8%$3.9m5.62m+26%added
ARQT ARCUTIS BIOTHERAPEUTICS INCHealthcare0.8%$3.8m268,000–new
DOCS DOXIMITY INCHealthcare0.7%$3.7m60,000−51%reduced
XENE XENON PHARMACEUTICALS INCHealthcare0.7%$3.4m107,891−53%reduced
VRNA VERONA PHARMA PLC–0.6%$3.2m33,800–new
UNIQURE NV no ticker–0.6%$2.9m207,000−38%reduced
APGE APOGEE THERAPEUTICS INCHealthcare0.6%$2.8m65,000–new
SLNOEUR SOLENO THERAPEUTICS INC–0.5%$2.7m32,0000.0%held
CAH CARDINAL HEALTH INCHealthcare0.5%$2.5m15,000–new
SPRY ARS PHARMACEUTICALS INCHealthcare0.5%$2.4m140,000–new
2KZ0 KEZAR LIFE SCIENCES INC–0.5%$2.3m502,6000.0%held
NTLA INTELLIA THERAPEUTICS INCHealthcare0.4%$2.2m232,000–new
MLTX MOONLAKE IMMUNOTHERAPEUTICSHealthcare0.4%$1.8m39,000–new
ARVN ARVINAS INCHealthcare0.4%$1.8m243,162−41%reduced
SNDX SYNDAX PHARMACEUTICALS INCHealthcare0.3%$1.4m150,000−84%reduced

Exited since Q1 2025

25 rows
REGN REGENERON PHARMACEUTICALS3.3%$16.1m
GKOS GLAUKOS CORP2.7%$13.2m
JAZZ JAZZ PHARMACEUTICALS PLC2.0%$9.9m
NBIX NEUROCRINE BIOSCIENCES INC2.0%$9.5m
XBI SPDR SERIES TRUST1.6%$7.6m
CNTA CENTESSA PHARMACEUTICALS PLC1.6%$7.6m
AVTR AVANTOR INC1.5%$7.3m
IDYA IDEAYA BIOSCIENCES INC1.5%$7.3m
JANX JANUX THERAPEUTICS INC1.4%$7.0m
2655787D BLUEPRINT MEDICINES CORP1.3%$6.1m
UTHR UNITED THERAPEUTICS CORP DEL1.1%$5.2m
BRKR BRUKER CORP1.0%$4.8m
BHVN BIOHAVEN LTD0.7%$3.5m
ACAD ACADIA PHARMACEUTICALS INC0.6%$2.8m
RPRX ROYALTY PHARMA PLC0.6%$2.7m
CAPR CAPRICOR THERAPEUTICS INC0.5%$2.3m
LXEO LEXEO THERAPEUTICS INC0.5%$2.2m
VERA VERA THERAPEUTICS INC0.5%$2.2m
RGNX REGENXBIO INC0.4%$1.9m
IONS IONIS PHARMACEUTICALS INC0.4%$1.8m
MIRM MIRUM PHARMACEUTICALS INC0.4%$1.8m
NEWAMSTERDAM PHARMA COMPANY no ticker0.3%$1.4m
AGL AGILON HEALTH INC0.3%$1.3m
PCVX VAXCYTE INC0.2%$868k
HYPR HYPERFINE INC0.03%$159k

Sector mix

  • Healthcare90.0%
  • Unclassified6.2%
  • Basic Materials3.8%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters